Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer

Although targeted drugs improved the therapeutic effect of HER2-positive breast cancer, the long-term prognosis was still poor. In this regard, the research and development of antibody-drug conjugates (ADCs) came into being and made a lot of progress. ADCs had the characteristics of both chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yongchao, Wang, Jin, Liao, Dongying, Zhang, Dou, Li, Xiaojiang, Jia, Yingjie, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747846/
https://www.ncbi.nlm.nih.gov/pubmed/36532256
http://dx.doi.org/10.2147/BCTT.S384830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747846/
https://www.ncbi.nlm.nih.gov/pubmed/36532256
http://dx.doi.org/10.2147/BCTT.S384830

Ejemplares similares